Takeda Reports Q3 FY2025 Earnings Results with Updated Guidance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Businesswire
- Revenue Performance: Takeda's Q3 FY2025 revenue reached ¥3,411.2 billion, a 3.3% year-on-year decline primarily due to VYVANSE generics; however, the company raised its full-year forecasts based on cost discipline and favorable FX effects.
- Profit Growth: The operating profit for Q3 was ¥422.4 billion, reflecting a 1.2% increase year-on-year, demonstrating the effectiveness of the company's operational efficiency improvements and cost management, with expectations to meet core operating profit guidance.
- New Drug Applications: Takeda has submitted NDAs for oveporexton and rusfertide, with plans to file for zasocitinib within the next 18 months, each having the potential to redefine care standards and drive long-term growth for the company.
- Strategic Positioning: CFO Milano Furuta emphasized that FY2025 is pivotal for Takeda as the company prepares for multiple innovative product launches aimed at improving patient lives and delivering long-term shareholder value.
Analyst Views on TAK
Wall Street analysts forecast TAK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TAK is 18.00 USD with a low forecast of 18.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 16.910
Low
18.00
Averages
18.00
High
18.00
Current: 16.910
Low
18.00
Averages
18.00
High
18.00
About TAK
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
